with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue ...

KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.

Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health authority ...

Hyderabad-based Dr Reddy's Laboratories (DRL) posted a 9.5 per cent year-on-year (Y-o-Y) decline in its consolidated profit ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

According to the WHO, about 40 percent of pharmaceutical products are based on natural sources, and 70 percent of people ...